Dartmouth drug discovery company IMV is replacing its CEO.
Former Chief Executive Frederic Ors stepped down Wednesday, with Chief Business Officer Andrew Hall slated to serve as interim CEO until the Board of Directors hires a permanent replacement for Ors.
IMV is developing “a new class of targeted cancer immunotherapies” and has developed compounds that allow for the delayed release of anti-cancer drugs, aiming to administer medications in a way that is more compatible with patients’ immune systems.
“During Fred’s tenure, IMV successfully established the company’s proprietary technology